This DAB2IP-Wnt/β-catenin-NLGN3/NRXN3 network affecting GBM-CSC properties may help to develop potential therapeutic strategy by targeting Wnt/β-catenin to overcome therapy resistant GBM. Here, NLGN3 is linked to glioblastoma.